hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang下一页:综述:癫痫持续状态诊治最新进展
- 2022-04-11UCB的Vimpat癫痫新适应症在美国获批
- 2022-04-07抗癫痫药物预防新发癫痫:任重而道远
- 2022-04-06癫痫发作对中风患者静脉溶栓的长期转移有效
- 2022-04-05【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 2022-04-04FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 2022-04-04预测癫痫患者再入院风险
- NeuroImage:纤维球成像可用于癫痫的进展
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 综述:癫痫持续状态诊治最新进展
- 2013国际抗癫痫联合会抗癫痫药用指南
- 心率多少正常 如何保持正常心率不变
- 儿童癫痫的早期症状 癫痫的原因
- 脑梗死的症状是什么有这些前兆要谨慎
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- FDA批准Aptiom用于治疗患者癫痫发作
- 月经性癫痫患者妊娠期癫痫控制更好
- 癫痫病频频发作怎么办
- 2015 神经系统疾病诊疗成效大盘点
- 女性癫痫基因突变吗 癫痫病人怎样生出健康宝宝
- 不伴颞叶内侧硬化的颞叶癫痫患者隔核缩小
- 癫痫病的早病症是什么样的
- 得了羊角风有什么疼痛
- 癫痫病频发的病变有哪些
- 【病患问答】控制癫痫患者再抽搐, 可选用的药物不包括?
- 怎样识别癫痫病的早期预示
- Circ Ep:左室纤细的高血压患者新发房颤增加SCD风险
- 睡着时突然抽搐一下 新生儿睡着抽搐怎么办
- FDA 批准首个含活性成分的药物主要用途治疗罕见严重性癫痫
- 癫痫病吃什么可以管控
- 少用的癫痫病发作的症状有哪些
- 学龄前癫痫有哪些病因
- 教练癫痫发作,都是救生惹的祸?
- 引起癫痫病发作的各种因素有哪些
- 快速上手指南:惊厥病态癫痫持续状态监护与治疗
- 小儿病症的早期症状 病症的原因
- 普瑞巴林单药治疗法部分性癫痫发作安全有效
- 怎样化疗癫痫病最有效
- 少用的癫痫病的发病症状有哪些
- 孩童癫痫病病因有哪些
- 研究指为猪肉绦虫患者的癫痫由p物质引起
- 小孩癫痫病怎么科学外科手术
- 治疗腹型癫痫病必需多少钱
- 专家告诉你癫痫病的治疗好分析方法
- 癫痫持续精神状态应该如何处理?
- 20120816cctv10健康之路:周文静揭秘视网膜结构